Spastic paraplegia type 3A
آخر تحديث 27 Apr 2021
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
Spastic paraplegia type 3A is one of a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterised by muscle stiffness (spasticity) and weakness in the lower limbs (paraplegia). Hereditary spastic paraplegias are often divided into two types: pure and complex. The pure types involve only the lower limbs, while the complex types also involve other areas of the body; additional features can include changes in vision, changes in intellectual functioning, difficulty walking, and disturbances in nerve function (neuropathy). Spastic paraplegia type 3A is usually a pure hereditary spastic paraplegia, although a few complex cases have been reported.
اختيارات الفيديو لـ الحالات الوراثيةمكتبة الفيديو
الوصف
Spastic paraplegia type 3A is one of a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterised by muscle stiffness (spasticity) and weakness in the lower limbs (paraplegia). Hereditary spastic paraplegias are often divided into two types: pure and complex. The pure types involve only the lower limbs, while the complex types also involve other areas of the body; additional features can include changes in vision, changes in intellectual functioning, difficulty walking, and disturbances in nerve function (neuropathy). Spastic paraplegia type 3A is usually a pure hereditary spastic paraplegia, although a few complex cases have been reported.
In addition to spasticity and weakness, which typically affect both legs equally, people with spastic paraplegia type 3A can also experience progressive muscle wasting (amyotrophy) in the lower limbs, reduced bladder control, an abnormal curvature of the spine (scoliosis), loss of sensation in the feet (peripheral neuropathy), or high arches of the feet (pes cavus). The signs and symptoms of spastic paraplegia type 3A usually appear before the age of 10; the average age of onset is 4 years. In some affected individuals the condition slowly worsens over time, sometimes leading to a need for walking support.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal dominant. More than one pattern can apply in different cases.
Related genes
Other names
Spastic paraplegia 3
Spastic paraplegia 3A
SPG3A
Related patient information and medicines

Patient information leaflet
الشلل الدماغي
This may be before the baby is born, during the birth or soon after birth. What is cerebral palsy. Cerebral palsy is a name for a group of life-long conditions that have problems with muscle function and control. It is caused by brain injury or abnormal development of the brain that occurs while a child's brain is still developing. Types of.

Patient information leaflet
خلل التوتر العضلي
ت خلل التوتر العضلي is a lasting or frequently recurring and unwanted (involuntary) muscle contraction. It can affect one or more muscles in the body. There is no cure; however, there are different types of treatment which can help. Secondary dystonia Secondary means the dystonia ... It is not caused by your genetic make-up. Some neurological conditions.

Patient information leaflet
تلف الأعصاب بعد حقن فوق الجافية
ت spinal injection Spinal anaesthetic is given directly into the fluid that surrounds your الورم الدموي فوق الجافية الفقري cord (called the cerebrospinal fluid). The injection can be a local anaesthetic or a medicine to relieve pain. The risk of longer... Nerve damage to both legs (paraplegia) or death occurs between 1 in 54,500 to 1 in 141,500 الورم الدموي فوق الجافية الفقري or epidural.

Patient information leaflet
تخفيف الألم باستخدام الإيبيدورال بعد الجراحة
The content of this leaflet is used with the permission of the Royal College of Anaesthetists , the professional body responsible for the speciality throughout the UK, ensuring the quality of patient care through the maintenance of standards in anaesthesia, critical care and pain medicine. What is an epidural. An epidural is used for giving pain.

Patient information leaflet
ضمور العضلات
بعض genes control the proteins needed for muscle fibres to work properly. Genetic mutations can affect these genes, which are involved in MD. The 'faulty' gene in MD means that one of the proteins needed by muscle cells cannot be made correctly. The protein will either be lacking or will be a 'faulty' protein that does not work well. This leads.

Patient information leaflet
مرض باجيت العظمي
Paget's disease of bone affects the structure of parts of one or more bones. In most cases it causes no symptoms and does not need treatment. Symptoms develop in some cases and pain in the affected part of bone... What is Paget's disease of bone. Paget's disease of bone was first described by Sir James Paget in 1877. (It is a different condition.
قراءة إضافية ومراجع
- Spastic paraplegia type 3A; MedlinePlus, National Library of Medicine.
- Alvarez V, Sanchez-Ferrero E, Beetz C, Diaz M, Alonso B, Corao AI, Gamez J, Esteban J, Gonzalo JF, Pascual-Pascual SI, Lopez de Munain A, Moris G, Ribacoba R, Marquez C, Rosell J, Marin R, Garcia-Barcina MJ, Del Castillo E, Benito C, Coto E; Group for the Study of the Genetics of Spastic Paraplegia. Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia. BMC Neurol. 2010 Oct 8;10:89. doi: 10.1186/1471-2377-10-89.
- Blackstone C. Cellular pathways of hereditary spastic paraplegia. Annu Rev Neurosci. 2012;35:25-47. doi: 10.1146/annurev-neuro-062111-150400. Epub 2012 Apr 20.
- Ivanova N, Claeys KG, Deconinck T, Litvinenko I, Jordanova A, Auer-Grumbach M, Haberlova J, Lofgren A, Smeyers G, Nelis E, Mercelis R, Plecko B, Priller J, Zamecnik J, Ceulemans B, Erichsen AK, Bjorck E, Nicholson G, Sereda MW, Seeman P, Kremensky I, Mitev V, De Jonghe P. Hereditary spastic paraplegia 3A associated with axonal neuropathy. Arch Neurol. 2007 May;64(5):706-13. doi: 10.1001/archneur.64.5.706.
- Leonardi L, Marcotulli C, Santorelli FM, Tessa A, Casali C. De novo mutations in SPG3A: a challenge in differential diagnosis and genetic counselling. Neurol Sci. 2015 Jun;36(6):1063-4. doi: 10.1007/s10072-015-2097-1. Epub 2015 Jan 31. No abstract available.
- Leonardis L, Auer-Grumbach M, Papic L, Zidar J. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. Eur J Neurol. 2012 Jul;19(7):992-8. doi: 10.1111/j.1468-1331.2012.03665.x. Epub 2012 Feb 16.
- Namekawa M, Ribai P, Nelson I, Forlani S, Fellmann F, Goizet C, Depienne C, Stevanin G, Ruberg M, Durr A, Brice A. SPG3A is the most frequent cause of hereditary spastic paraplegia with onset before age 10 years. Neurology. 2006 Jan 10;66(1):112-4. doi: 10.1212/01.wnl.0000191390.20564.8e.
- Zhu PP, Soderblom C, Tao-Cheng JH, Stadler J, Blackstone C. SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development. Hum Mol Genet. 2006 Apr 15;15(8):1343-53. doi: 10.1093/hmg/ddl054. Epub 2006 Mar 14.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
27 Apr 2021 | أحدث إصدار
1 Mar 2015 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

